Form 4: Mineralys CEO Sells Shares Under 10b5-1 Plan

Mineralys Therapeutics CEO Jon Congleton sold 15,100 shares of common stock on October 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jon Congleton, Chief Executive Officer and Director of Mineralys Therapeutics, Inc. (MLYS), reported the sale of common stock.
• The transactions occurred on October 13, 2025.
• A total of 15,100 shares were sold in two separate transactions.
• The first transaction involved 13,548 shares at a weighted-average price of $42.6295, with individual sales ranging from $41.9800 to $42.9800.
• The second transaction involved 1,552 shares at a weighted-average price of $43.0299, with individual sales ranging from $42.9822 to $43.2030.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Congleton on January 30, 2024.
• Following these transactions, Mr. Congleton directly beneficially owns 831,305 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports a pre-planned insider stock sale under a Rule 10b5-1 plan, which is a routine event for personal financial management and not typically indicative of company-specific positive or negative news.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, adopted well in advance on January 30, 2024, indicating a planned and transparent approach to insider selling rather than a reaction to immediate, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, though the pre-planned nature mitigates concerns about immediate lack of confidence.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception of insider sales.

Future Outlook

This Form 4 filing reports an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information related to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: May note the insider sale, but the execution under a pre-arranged 10b5-1 plan suggests it is for personal financial planning rather than a reaction to new, material company-specific information, thus minimizing immediate concerns.

Key Dates

Keywords

MLYS, Mineralys Therapeutics, Jon Congleton, CEO, Director, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan